MedPath

Takeda Pharmaceutical Company Ltd

🇸🇪Sweden
Ownership
-
Established
1925-01-01
Employees
-
Market Cap
$47.5B
Website
http://www.takeda.co.jp/
Clinical Trials
Related News

Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus.

Phase 4
Completed
Conditions
Diabetes Mellitus
Interventions
Drug: Glibenclamide and Metformin
Drug: Pioglitazone and Metformin
First Posted Date
2008-10-10
Last Posted Date
2011-07-12
Lead Sponsor
Takeda
Target Recruit Count
39
Registration Number
NCT00770835

Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

Phase 3
Completed
Conditions
Diabetes Mellitus
Interventions
Drug: TAK-559
Drug: Placebo
First Posted Date
2008-09-30
Last Posted Date
2012-11-12
Lead Sponsor
Takeda
Target Recruit Count
302
Registration Number
NCT00763022

Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

Phase 3
Terminated
Conditions
Diabetes Mellitus
Interventions
Drug: TAK-559
First Posted Date
2008-09-30
Last Posted Date
2012-11-12
Lead Sponsor
Takeda
Target Recruit Count
316
Registration Number
NCT00762112

Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

Phase 3
Terminated
Conditions
Diabetes Mellitus
Interventions
Drug: TAK-559 and insulin
Drug: Insulin
First Posted Date
2008-09-30
Last Posted Date
2012-11-12
Lead Sponsor
Takeda
Target Recruit Count
348
Registration Number
NCT00762190

Efficacy and Safety Study of SYR-619 in Treating Subjects With Type 2 Diabetes Mellitus

Phase 2
Terminated
Conditions
Diabetes Mellitus
Interventions
Drug: Placebo
Drug: SYR-619
Drug: Alogliptin
First Posted Date
2008-09-30
Last Posted Date
2012-05-21
Lead Sponsor
Takeda
Target Recruit Count
82
Registration Number
NCT00763347

Safety and Efficacy of TAK-559 in Combination With Metformin in Patients With Type 2 Diabetes Mellitus.

Phase 3
Terminated
Conditions
Diabetes Mellitus
Interventions
Drug: TAK-559 and metformin
Drug: Metformin
First Posted Date
2008-09-30
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
15
Registration Number
NCT00762957

A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers

Phase 3
Terminated
Conditions
Stomach Ulcer
Duodenal Ulcer
Interventions
Drug: Lansoprazole
Drug: Gefarnate
First Posted Date
2008-09-30
Last Posted Date
2012-02-03
Lead Sponsor
Takeda
Target Recruit Count
461
Registration Number
NCT00762359

Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus

Phase 2
Completed
Conditions
Diabetes Mellitus
Interventions
Drug: Pioglitazone and azilsartan
Drug: Pioglitazone
First Posted Date
2008-09-30
Last Posted Date
2012-02-28
Lead Sponsor
Takeda
Target Recruit Count
704
Registration Number
NCT00762736

Efficacy and Safety Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

Phase 3
Terminated
Conditions
Diabetes Mellitus
Interventions
Drug: TAK-559
Drug: Placebo
First Posted Date
2008-09-30
Last Posted Date
2012-11-12
Lead Sponsor
Takeda
Target Recruit Count
8
Registration Number
NCT00762684

Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension

Phase 3
Completed
Conditions
Hypertension
Interventions
Drug: Ramipril
Drug: Azilsartan medoxomil
First Posted Date
2008-09-26
Last Posted Date
2012-11-15
Lead Sponsor
Takeda
Target Recruit Count
885
Registration Number
NCT00760214
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy